Axis inhibition protein 1 (AXIN1) mRNA (AXIN1 mRNA)

Axis inhibition protein 1 (AXIN1) mRNA encodes a critical scaffold protein that functions as the rate-limiting component of the beta-catenin destruction complex within the canonical Wnt signaling pathway (UniProt O15169). This complex, which also includes adenomatous polyposis coli (APC) and glycogen synthase kinase 3 beta (GSK3B), is responsible for the phosphorylation and subsequent proteasomal degradation of beta-catenin, thereby preventing its nuclear translocation and the activation of pro-proliferative genes (NCBI Gene ID: 8312). In many cancers, particularly hepatocellular carcinoma and colorectal cancer, AXIN1 is frequently mutated or down-regulated, leading to the stabilization of beta-catenin and the promotion of oncogenesis (Mazzoni and Fearon, 2014). Therapeutic strategies targeting the AXIN1 pathway primarily focus on increasing the levels of the AXIN1 protein to restore the destruction complex's function. Small molecules such as tankyrase inhibitors (e.g., XAV939) achieve this by preventing the poly-ADP-ribosylation of AXIN1, which otherwise marks it for degradation (Huang et al., Nature 2009). While direct targeting of AXIN1 mRNA via RNA-based therapies is an area of active research, the systemic inhibition of Wnt signaling remains a challenge due to potential toxicities in Wnt-dependent tissues like the bone and gastrointestinal tract.

Other names

AXIN1 transcriptAxis inhibitor 1 mRNAFused locus protein mRNAAXIN mRNA

Stabilization of AXIN1 protein through tankyrase inhibition to enhance beta-catenin degradation.